What is the standard management regimen for Hodgkin's lymphoma?

The standard management regimen for Hodgkin's lymphoma is ABVD, which stands for Adriamycin (doxorubicin), Bleomycin, Vinblastine, and Dacarbazine. This chemotherapy combination has been established as a standard treatment due to its effectiveness in achieving high cure rates while maintaining a relatively favorable safety profile compared to other regimens.

ABVD is specifically tailored for Hodgkin's lymphoma, targeting the specific characteristics of the lymphoma cells and minimizing toxicity to healthy tissues. This regimen is commonly used for early-stage and advanced-stage disease, making it a versatile option within the treatment protocol for this type of lymphoma.

Other options may have specific indications; for example, CHOP is commonly used for non-Hodgkin lymphomas, R-CHOP includes the addition of rituximab and is more relevant for non-Hodgkin lymphoma as well. BEACOPP could be used in specific situations or for more aggressive forms of Hodgkin's lymphoma but is not the standard frontline therapy. Therefore, ABVD remains the cornerstone of treatment for Hodgkin's lymphoma.